Articles tagged with Combination Therapies
Researchers found a way to improve the anti-cancer effect of Smac mimetics by inhibiting MK2 protein, leading to a potent new combination therapy for acute myeloid leukemia (AML). The discovery provides hope for developing safer and more powerful treatments for cancers with few treatment options.
Researchers have found that coupling an antibody with standard-of-care antiretroviral treatment reduces virus levels and reverses immune system damage in SIV-infected rhesus macaques. The dual therapy maintains undetectable virus levels for over nine months after ART withdrawal.
Researchers propose a novel combination therapy using resveratrol, antioxidants and iron chelators to slow down Alzheimer's disease progression. The addition of resveratrol may enhance cell viability and longevity by activating AMPK and sirtuin pathways.
An international clinical trial led by University of Pittsburgh Cancer Institute (UPCI) professor Atilla Soran found that surgery to remove the primary tumor followed by standard therapy adds months to patients' lives compared to standard therapy alone. Surgery resulted in nearly 42% of women living to five years after diagnosis.
A recent study found that HIV infection can lead to an average age acceleration of 4.9 years due to epigenetic changes, increasing the risk of mortality by 19%. The researchers suggest that early intervention and healthy lifestyle choices may help mitigate these risks.
Researchers at York University found that integrating motivational interviewing (MI) into cognitive behavioral therapy (CBT) is more effective in treating severe generalized anxiety disorder. This approach helps patients overcome conflicting feelings and enhances motivation for change, leading to improved long-term outcomes.
The Journal of Comparative Effectiveness Research discusses new recommendations from the Center for Medical Technology Policy's Green Park Collaborative for evaluating oncology treatment sequences. The framework developed by GPC-USA aims to fill evidence gaps and identify patient-important outcomes, ultimately improving cancer patient ...
Researchers presented landmark studies on newly diagnosed multiple myeloma, revealing key biological processes and disease mechanisms. Two combination therapy strategies showed high response rates in patients with difficult-to-treat myeloma.
Postmenopausal African American women who use female hormone supplements containing estrogen and progestin are at a 50% increased risk of estrogen receptor positive breast cancer. The study found greater increases in risk for recent and long-term users, highlighting the importance of limiting combination therapy.
A randomized clinical trial found bright light treatment alone and combined with fluoxetine to be effective treatments for adults with nonseasonal major depressive disorder. The study's primary outcomes showed that combination therapy and light therapy alone were superior to placebo, while fluoxetine alone was not.
A combination therapy of endovascular revascularization followed by supervised exercise resulted in greater improvement in walking distances and health-related quality-of-life measures at one year compared to supervised exercise only. This is a significant benefit for patients with peripheral artery disease and intermittent claudication.
A randomized clinical trial found that monotherapy with β-lactam alone was not inferior to combination therapy with a macrolide for patients hospitalized with moderately severe pneumonia. The study suggested that dual antibiotic therapy may be necessary to treat atypical pathogens and prevent readmissions.
A phase 3 trial found that combining dabrafenib with trametinib significantly reduces disease progression and death risk in metastatic melanoma patients. The therapy results in a 67% complete or partial response rate compared to 51% on monotherapy.
Combination therapy with vemurafenib and cobimetinib achieves greater progression-free survival and response rates than vemurafenib alone in BRAF-mutation positive melanoma. The study also shows a reduced incidence of skin-related side-effects with combination therapy.
A study found that combination therapy with long-acting beta-agonists (LABAs) and inhaled corticosteroids (ICSs) is associated with a lower risk of death or COPD hospitalization among older adults with COPD, particularly those with asthma. The therapy also showed promise for patients without asthma.
A new study from the University of Pennsylvania School of Medicine reveals that weight loss is the single most important factor for improving cardiovascular health in obese obstructive sleep apnea (OSA) patients. Weight loss alone significantly reduced inflammation, insulin resistance, dyslipidemia, and high blood pressure.
Studies show sequential combination therapy with peginterferon and nucleoside analogues results in high complete response and HBsAg loss rates. Baseline HBsAg level and rate of decline during treatment predict treatment response. Adding peginterferon to entecavir enhances response rates, viral decline, and facilitates discontinuation.
Researchers at USF Health have found that a combination of human umbilical cord blood cells and granulocyte colony stimulating factor significantly reduced TBI-induced loss of neuronal cells in the hippocampus. The therapy also showed beneficial results in animals with experimental TBI, with G-CSF alone producing short-lived benefits.
Combining varenicline and bupropion for smoking cessation showed increased quit rates in heavier and more dependent smokers. However, the effects were similar in lighter smokers using varenicline alone.
A combined therapy of adrenocorticotropic hormone, topiramate, vitamin B6, and immunoglobulin effectively improves infantile spasms prognosis. This treatment is superior in cryptogenic children compared to symptomatic ones. The study published in Neural Regeneration Research
Researchers found that patients with pulmonary arterial hypertension (PAH) receiving IV PGI2 combination therapy experienced higher pulmonary vascular resistance, mean number of PAH-related hospitalizations, and dyspnea scores compared to those on monotherapy or non-IV PGI2 combination therapy. This study was presented during CHEST 2012.
A 25-year follow-up study found that 68% of juvenile myoclonic epilepsy patients became seizure-free, with nearly 30% no longer needing antiepileptic drug treatment. AED polytherapy and generalized tonic-clonic seizures preceding bilateral myoclonic seizures predicted poor long-term seizure outcomes.
A recent study published in JAMA found that combining antibiotics did not improve clinical outcomes for patients with severe sepsis. The study included 298 patients who received either combination therapy or monotherapy, and found no significant difference in organ failure scores or mortality rates between the two groups.
Patients taking SSRIs with antiplatelet therapy have a higher risk of bleeding compared to those taking ASA alone. The study found that combining an SSRI with ASA increased the risk by 42%, while dual antiplatelet therapy increased the risk by 57%. Women and patients who underwent angioplasty had lower bleeding risks.
A new study found that combining a mandibular advancement splint with positive airway pressure therapy significantly improves treatment outcomes for patients with severe obstructive sleep apnea. The study showed a mean AHI of 2.6 events per hour with combined therapy, compared to 4.4 events per hour with CPAP alone.
A study published in CMAJ found that elderly patients taking combination ACE inhibitors and ARBs had a higher risk of kidney failure and death. The researchers observed that most patients stopped the combination therapy within three months due to low blood pressure.
A study compared balanced propofol sedation with conventional sedation for therapeutic GI endoscopic procedures, finding higher health care provider satisfaction and better patient cooperation in the BPS group. The results show that BPS provided similar adverse event profiles to conventional sedation.
Bevacizumab, a cancer treatment drug, increases the risk of fatal adverse events (FAEs) when combined with chemotherapy or biological therapy. According to a review of published trials, the overall incidence of FAEs was 2.5%, with a significant increase in patients receiving taxanes or platinum agents.
A study found that combining epigenetic therapy and molecular targeted therapy can improve outcomes for patients with elevated E-cadherin levels in advanced lung cancer. The treatment achieved significantly improved overall survival rates compared to erlotinib alone.
A study of over 800 epileptic patients found that individual susceptibility, AED type, and physician skills are key factors determining adverse effects. Despite high polytherapy rates, no major difference was observed in adverse effect frequency between monotherapy and polytherapy groups.
A study published in the New England Journal of Medicine found that patients with moderate to severe Crohn's disease who received combination therapy with infliximab and azathioprine had a higher chance of achieving remission compared to those treated with azathioprine alone. The researchers also discovered comparable safety results ac...
A new study published in The Lancet found that combination therapy does not improve overall or progression-free survival compared to single therapy for renal cell carcinoma. However, the combined regimen may still benefit a small number of patients by producing long remissions.
A new study demonstrates advances in optimizing treatments and quality of life for patients with multiple myeloma. The research explores optimal induction therapies, advance care planning, and a potential new first-line therapy for non-Hodgkin lymphoma.
The majority of malaria endemic countries adopted effective artemisinin combination therapy more than three years ago, but its availability remains low in public and private sectors. Ineffective monotherapies dominate the market share in many countries, with some products costing up to 65 times the minimum daily wage.
A recent UCLA study found that women developing new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy are at a significantly higher risk of developing breast cancer. The research analyzed data from over 16,000 participants in the Women's Health Initiative clinical trial.
The study reports on the short and mid-term outcomes of TAVI in 120 consecutive patients with severe symptomatic aortic stenosis, achieving a one-year survival rate of 79%. The most important predictor of late mortality was related to the learning curve, highlighting the necessity of proper training and high-volume centers.
A Phase IIb clinical trial shows that adding a hepatitis C protease inhibitor called telaprevir to standard therapy can significantly improve the chances of being cured, with a 67% cure rate in patients treated for 24 weeks. The treatment also reduces side effects and treatment duration compared to standard therapy alone.
A new combination therapy of daily consensus interferon and ribavirin is effective for some people with chronic hepatitis C, particularly those with lower fibrosis scores. Nearly half of all HCV patients do not respond to standard therapy, and this treatment shows promise as an alternative.
Researchers discovered that Oncostatin M improves interferon's antiviral effect, increasing immune response to viruses. This combination may be useful for treating chronic viral hepatitis and other tumors that don't respond to conventional therapy.
The five-year study aims to determine which rehabilitation therapies are most successful in improving outcomes for patients with different types and severities of traumatic brain injuries. The researchers will analyze data from over 2,300 patients to identify effective treatments.
A Phase I study combining Revlimid and Vidaza found the combination was well-tolerated and had high activity in treating higher-risk myelodysplastic syndromes (MDS). The therapy resulted in a 39% complete response rate and 72% overall response rate among patients.
A study found that ACTs could reduce malaria transmission by up to 53% in areas of low transmission, compared to 21% in high transmission areas. Long-acting antimalarial regimens may be needed in high transmission settings to achieve significant reductions.
A new ACP clinical practice guideline states that second-generation antidepressants are equally effective in treating depression but have different adverse effects. The guideline recommends assessing patient status and modifying treatment if necessary, to maximize therapeutic response while minimizing side effects.
A study found laser therapies to be safer when used separately, with more effective leg hair removal. Alexandrite lasers showed long-term efficacy, but caused higher pain severity and hyperpigmentation compared to Nd:YAG lasers.
The study found that alternative therapies such as acupuncture, massage, and exercises are effective in managing most common neck pain. The Task Force also recommends a grading system to classify neck pain, with Grade 1 being mild and Grade 4 indicating serious pathology.
A study of 1835 antiretroviral-naive patients found that those with suppressed HIV viral loads could see significant increases in CD4 cell counts over time, even after five years on treatment. Patients with low initial CD4 counts showed substantial rises in counts.
A new study from Karolinska Institutet shows naprapathy to be more effective in reducing back and neck pain, with 57% of patients reporting significant improvement after 12 weeks. The therapy combines manual manipulation and muscle treatments, offering a potential alternative to conventional medical advice.
A clinical trial evaluated three leading combination therapies for uncomplicated falciparum malaria and found artemether-lumefantrine to be the most effective. The study included 601 healthy children from Uganda and demonstrated significant reductions in treatment failure, anemia, and asymptomatic parasitemia.
Researchers discovered statins inhibit HCV replication without killing host cells. Fluvastatin showed strongest effect in combination with interferon, leading to effective HCV RNA replication inhibition.
A literature review provides evidence-based recommendations on treating severe asthma exacerbations with oral corticosteroids and questioning the practice of doubling ICS doses. The review also explores increasing ICS to high doses as an alternative to OCS.
The World Hypertension League is calling for better awareness of high blood pressure patients reaching the internationally-recognised goal of 140/90mmHg or lower. Despite this, around 50-70% of people with high blood pressure worldwide remain above this goal, leaving them at significant risk of cardiovascular disease.
A prospective study found that combining DETROL LA with standard treatment for enlarged prostate results in improved symptoms of overactive bladder, with 73% of patients experiencing relief. The most common side effects were dry mouth and dizziness.
Researchers found that combining 308-nm excimer laser therapy with topical tacrolimus ointment resulted in 100% repigmentation in group A lesions and 85% in group B. The treatment was well tolerated, with an average of 10-12 sessions needed to see improvement.
A Phase III trial found that CAMPTOSAR combinations with select targeted agents improve survival for MCRC patients. The combination of Avastin and IFL yields an average survival of 25.1 months compared to 15.8 months with IFL alone. A Phase II trial also shows the efficacy of Erbitux plus CAMPTOSAR and infusional FOLFIRI in EGFR-expres...
The CAMPTOSAR plus cisplatin regimen demonstrated improved one-year survival rates (59.2%) and response rates (31%) compared to current standard treatments. Patient toxicities were also significantly reduced, with fewer grade 3-4 neutropenia and thrombocytopenia cases.
A study by Chandra P. Belani and colleagues found that elderly patients with advanced NSCLC can tolerate combination therapy safely and effectively, with median survival rates comparable to those of younger patients. The treatment regimens used in the study were weekly paclitaxel in combination with full doses of carboplatin.
Researchers found that patients with combined devices showed significant improvements in quality of life, physical functioning, and exercise capacity compared to those without the devices. The study's findings have implications for treating heart failure, a disease with a five-year mortality rate of 50 percent after diagnosis.
A new study published in JAMA found that a combination therapy of hormone replacement and alendronate was well-tolerated by elderly women with low bone mass. After three years, participants taking the combination therapy showed significantly greater increases in bone mass compared to those taking individual therapies.
Researchers found that aspirin use did not decrease the effectiveness of ACE inhibitor therapy in patients. The combination of both treatments significantly reduced major vascular outcomes by 22%, producing substantial additional benefits for patients at high risk of events.
A nationwide survey of over 800 adults found that patients who use both traditional and CAM therapies view their healthcare providers as part of a larger team. More than half of respondents believed CAM therapies were more helpful for certain conditions, but had equal trust in physicians as practitioners.